NPPB and chronic kidney disease: Since some of the most commonly used biomarkers for these purposes (e.g., troponin or brain natriuretic peptide (BNP)) are chronically elevated in patients with CKD [57,58], novel cardiovascular biomarkers are warranted to facilitate the management of patients with decreased renal function.